A new federal THC threshold is set to reshape what counts as a legal hemp product, and the industry is not waiting quietly to find out how it lands. The cap, originally slated for November 12, 2026, and now pushed to December 11 after a short-term funding bill cleared the House in September, would limit hemp products to 0.3% total tetrahydrocannabinols or 0.4 mg total THC per container. According to Jonathan Miller, general counsel for the US Hemp Roundtable, that 0.4 mg threshold "would ban 95% of products currently on the market." That is not a rounding error. That is most of a category.
A Loophole Closes, But the Fix Is Messy
The 2018 Farm Bill drew a line between marijuana and hemp based on delta-9 THC concentration, and in doing so it opened a side door for intoxicating hemp-derived products that nobody in Congress specifically authorized. Lawmakers have spent the years since trying to shut that door without taking the hinges off the whole structure. The trouble, as Alleh Lindquist, director and CEO of FloraWorks, points out, is that broad statutory language can sweep in more than intended. "If interpreted too broadly, that language could call into question standard hemp-processing methods such as extraction, purification, THC remediation, distillation, and decarboxylation," he says. In other words, the same techniques used to produce non-intoxicating, remediated CBD oil could get caught in a net meant for synthetic THC products. That is the regulatory equivalent of closing a bridge to stop jaywalkers.
Meanwhile, signals from the White House point a different direction. Executive Order 14370, signed in December 2025, called for updating the hemp-derived cannabinoid product definition to preserve access to full-spectrum CBD products while still restricting items that carry real health risk. Separately, the administration in June 2026 pushed for revisions aligned with Amendment #54 to H.R. 8646, or at minimum an extension of the implementation timeline under Section 781 of Public Law 119-37. In July, Representatives Andy Barr and Angie Craig introduced the Lawful Hemp Protection Act, aimed at building a durable federal framework rather than a patchwork of emergency extensions.
What It Looks Like From Inside a Hemp Business
FloraWorks makes a purified cannabinol ingredient called TruCBN, and because the company sells a purified cannabinoid rather than a finished product with quantifiable THC, Lindquist says the 0.4 mg cap is largely immaterial to its own operation. That does not mean the company is indifferent to the outcome. "This provision is not material to our business, but it will have a significant impact across the broader hemp industry, including full-spectrum ingredients and products, as well as higher-THC hemp products intended for intoxication," he notes. Full-spectrum CBD brands, in particular, have less room to maneuver than single-cannabinoid manufacturers.
FloraWorks is pursuing a New Dietary Ingredient Notification with the FDA for TruCBN, with submission still on track for later this year. Its toxicology work has gone through peer review, and a Self-Affirmed GRAS determination is now in independent expert panel review - the kind of documentation trail regulators and institutional buyers increasingly expect before a cannabinoid ingredient gets anywhere near a formal healthcare setting. Lindquist also points to real-world evidence, including an observational sleep study the company is running on TruCBN, as a way to build safety and efficacy data where large randomized trials remain scarce.
State Patchwork Is the Operational Headache, Not Just the Cap
Ask operators what actually keeps them up at night, and it is rarely the federal number itself - it is the dozen-plus states that have already gone further. Miller notes that states including Ohio and Illinois have added severe restrictions on hemp products since November, joining a growing list of jurisdictions unwilling to wait for Congress. For companies selling across state lines, the compliance burden is not just about meeting a THC ceiling on the label. "The bigger challenge is navigating inconsistent testing, documentation, licensing, and quality standards," Lindquist says. Some states require in-state licensing, a local physical presence, or distribution through in-state partners - requirements that have nothing to do with potency and everything to do with paperwork.
- Inconsistent lab testing protocols across states complicate COA comparisons for multi-state brands
- Licensing and in-state presence requirements add cost regardless of product formulation
- Age restrictions and THC caps mainly affect finished-product labeling, not raw ingredient supply
- Reimbursement pathways, including CMS's newly launched Substance Access Beneficiary Engagement Incentive, are untested territory for hemp-derived ingredients
What Brands Should Actually Do Between Now and the Deadline
Here is the catch: nobody interviewed is predicting a clean resolution by the new December date, and nobody is predicting total collapse either. Miller describes the trade association's posture as "cautiously optimistic," pointing to presidential support for a legislative fix while adding, "whatever happens, we will not give up the fight." Lindquist's advice to brands is less about hope and more about discipline. "We do not expect an immediate disruption to our supply chain on November 12," he says. "We are continuing to monitor implementation closely and are advising customers to stay informed, review their product portfolios, and avoid making unnecessary changes before there is clearer guidance on how the new definitions will be applied."
That is a reasonable posture for an industry that has been burned before by moving too fast on partial information. Reformulating a product line, renegotiating wholesale contracts, or pulling SKUs off shelves based on a deadline that has already shifted once carries its own risk. The more durable approach, for now, looks like documentation: clean COAs, batch records, and a formulation strategy that can adapt to whichever definition of "non-intoxicating" eventually survives the legislative process.
